Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study - Takeaways - MDSpire

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

  • By

  • Huilin Lu

  • Tao Xu

  • Jing Li

  • Bufu Tang

  • Yulan Zeng

  • Xinghai Li

  • Jiangping Cun

  • Xiangwen Xia

  • Jihong Hu

  • Xuancheng Xie

  • Hongjie Fan

  • May 29, 2026

  • 0 min

Share

  • 1

    Icaritin combined with TACE significantly improves overall survival and progression-free survival in advanced HCC patients with macrovascular invasion.

  • 2

    The median overall survival was 16.3 months for the Icaritin–TACE group compared to 13.3 months for the TACE monotherapy group.

  • 3

    The disease control rate was higher in the Icaritin–TACE group at 84.0% versus 72.2% in the TACE alone group.

  • 4

    Independent predictors of overall survival included ECOG performance status, alpha-fetoprotein levels, lesion number, and maximum lesion diameter.

  • 5

    The overall incidence of adverse events was similar between the Icaritin–TACE and TACE monotherapy groups.

Original Source(s)

Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

  • by Huilin Lu, Tao Xu, Jing Li, Bufu Tang, Yulan Zeng, Xinghai Li, Jiangping Cun, Xiangwen Xia, Jihong Hu, Xuancheng Xie, Hongjie Fan

  • May 29, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen